Equivalent reductions in cigarette biomarkers between smokers who switched to JUUL and those who refrained from smoking

SAN FRANCISCO, February 23, 2019 / PRNewswire / – Juul Labs today announced the results of a clinical study revealing equivalent reductions in certain short-term exposure biomarkers (BOE) in adult smokers who switched exclusively to JUUL products and among those who had refrained from smoking for five days. The results of the study, "Changes in exposure biomarkers badociated with a change in nicotine salt pellet system for five days, from one cigarette to another", were presented at the annual meeting 2019 of the American Society for Research on Nicotine and Tobacco San Francisco, CA.

The study, a randomized, open-label, parallel group, and adult smoking study, was sponsored by Juul Labs and conducted by Celerion, Inc., a third-party research laboratory. He examined the changes, from baseline, of primary BOE in urine and blood in 90 adult smokers. The selected short-term biomarkers, NNN, NNAL, 3-HPMA, MHBMA, S-PMA, HMPMA, CEMA, 1-OHP and COHb, are carcinogens observed during the use of combustible cigarettes and are widely recognized as contributing to tobacco. cancers related to cancer.

The subjects in the study were randomized into six groups and used, for five days, a nicotine salt pod system (NSPS / JUULpod), refrained from smoking or continued use. of their usual brand of cigarettes. NSPS users were then randomized into four distinct groups (15 subjects per group) and used one of the four 5% nicotine-flavored products (Virginia Tobacco, Mint, mango or cream). Before reference reading, subjects had refrained from smoking for 12 hours to badess the impact on alcohol consumption, the use of the NSPS, abstinence, or the consumption of cigarettes.

The study found that the eight nicotine-free urine BOE had been reduced by 85.3% in the abstinence group, compared to an overall reduction of 85.0% in the pooled NSPS group (p>>). 0.05). This represents a relative reduction of 99.6% in the total number of BOEs for the pooled NSPS group. In the group of cigarettes, the same boe increased by 14.4% compared to the base.

"We are very pleased to share these results with other SRNT 2019 researchers, who continue to demonstrate the potential positive impact of vapor-based products," said Kevin Burns, General Manager of Juul Labs. "The equivalent reductions in these cigarette-specific biomarkers in the non-smoking groups and those who used the JUUL products reaffirm the role that vapor-based products can have for the adult smoker. dependence, nicotine is not directly responsible for cancers commonly cigarette smoking, it is rather the harmful components present in the combustible smoke.The more we can eliminate cigarettes, the greater the impact on public health will be. We commit to conducting rigorous scientific research to contribute to the ongoing dialogue on steam-based products and hope to share additional research with the medical, scientific and public health communities. "

In accordance with FDA regulations, Juul Labs can not and does not claim that its products are less harmful or safer than cigarettes.

For more information on the data presented at SRNT 2019, please visit jliscience.com.

About Juul Labs, Inc.

Juul Labs is committed to improving the lives of one billion adult smokers worldwide by eliminating cigarette smoking, the leading cause of preventable death in the world. Juul Labs & # 39; the products are designed to help smokers to change.

Juul Labs is also committed to combating the consumption of nicotine and tobacco by minors. The company has launched a comprehensive action plan to limit access, appeal and use of young people, including limiting the sale of some flavored JUULpod to traditional trade, by improving online age verification, improving the compliance of retailers, eliminating the use of Facebook and Instagram accounts and using technology. solutions based on prevention of use by young people. We are also actively supporting the Tobacco 21 legislation to raise the minimum age for the purchase of all tobacco products, including steam-based products, at 21 years of age. For more information on our mission and youth prevention initiatives, please visit https://newsroom.juul.com/.

Media Contacts

[email protected]

View the original content to download the multimedia: https: //www.prnewswire.com/news-releases/equivalent-reductions-in-cigarette-related-biomarkers-between-smokers-who-switched-to-juul-and-those -whose-a-content-of-cigarettes-300800835.html

SOURCE JUUL Labs, Inc.